Anavex Life Sciences Corp (AVXL)

[georgejjl]

Alzheimer’s disease:

Full data from the blarcamesine in Alzheimer’s disease Phase 2b/3 placebo-controlled clinical trial will be published in an upcoming peer-reviewed journal.

The initiated process for submitting a Marketing Authorisation application to the European Medicines Agency (EMA) under the Centralised Procedure is underway. The Marketing Authorisation would allow direct market access throughout the European Union for oral blarcamesine for the treatment of Alzheimer’s disease. There are an estimated 7 million people in Europe with Alzheimer’s disease, a number expected to double by 2030, according to the European Brain Council.[2]

Analysis of RNA sequencing (RNA-seq) of the placebo-controlled Phase 2b/3 blarcamesine trial in early Alzheimer’s disease is underway. Interim data expected by mid 2024.

Ongoing ATTENTION-AD open-label extension 96-week trial. Interim data expected in the second half of 2024.

https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-second-quarter-financial-results-and-provides-businessd

Good luck and GOD bless,